Pharvaris (PHVS) is climbing 3% after investment bank JMP Securities raised its price target on the shares to $55, based on ...

JMP Securities maintained a positive outlook on Kalvista Pharmaceuticals Inc (NASDAQ:KALV), reiterating a Market Outperform ...

JMP Securities initiated coverage on Kalvista Pharmaceuticals Inc (NASDAQ: KALV), assigning a Market Outperform rating and setting a price target of $19.00. Currently trading at $8.77, the stock has ...

Jonathan Wolleben, an analyst from JMP Securities, has initiated a new Buy rating on KalVista Pharmaceuticals (KALV).Invest with Confidence: ...

Analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of KalVista Pharmaceuticals in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst P.

Electric Mind, a leading strategy and technology consultancy, announces its expansion into the United States with the opening of a new office in Chicago. This milestone marks a significant step in the ...

Key takeaways      While Generative AI (GenAI) technology continues to advance at incredible speed, organizational change has been hard work ? with more than two-thirds of respondents reporting that ...

KalVista (KALV) announced that Japan’s Ministry of Health, Labour and Welfare, or MHLW, has granted sebetralstat orphan drug designation. The ...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has ...

2. DRI Healthcare Trust acquires royalty stake in Sebetralstat sales DRI Healthcare Trust, an affiliate of healthcare royalty PE firm DRI Capital, also announced in November that it acquired a ...

1 Day KALV 6.22% DJIA 1.65% Russell 2K 1.99% Health Care/Life Sciences -3.18% ...

The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). Receive News & Ratings for KalVista ...